MedTrace Logo

Efflux Pump Mediated Azole Resistance in Candida Albicans

NCT03659162 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-09-06

No results posted yet for this study

Summary

Candida albicans is the major fungal pathogen causing infections in humans, ranging from superficial mucosal infection to systemic mycoses. In recent years, Candida infections have increased disproportionately as a result of the increased number of compromised host populations, such as patients with AIDS, diabetes and various cancers, and organ-transplant recipients. Severe oro-pharyngeal candidiasis afflicts many AIDS patients and is a significant infection in cancer patients being treated with chemotherapy and/or radiotherapy.

Conditions

Interventions

DRUG

Azole Antifungal

oral gel \& injections

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-17
Primary Completion
2019-04-10
Completion
2019-07-24

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659162 on ClinicalTrials.gov